Long-lasting effects of a PEGylated mutant cocaine esterase (CocE) on the reinforcing and discriminative stimulus effects of cocaine in rats

Neuropsychopharmacology

Volumn 37, Issue 5, 2012, Pages 1092-1103

  Collins, Gregory T ^a,b   Narasimhan, Diwahar ^a   Cunningham, Alyssa R ^a   Zaks, Matthew E ^a   Nichols, Joseph ^a   Ko, Mei Chuan ^a   Sunahara, Roger K ^a   Woods, James H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

cocaine; cocaine esterase; drug discrimination; methlyphenidate; PEG CCRQ CocE; self administration

Indexed keywords

CARBOXYLESTERASE; DEXAMPHETAMINE; MACROGOL; METHYLPHENIDATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG SELF ADMINISTRATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LETHALITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CARBOXYLIC ESTER HYDROLASES; COCAINE; CONDITIONING, OPERANT; DISCRIMINATION (PSYCHOLOGY); DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FOOD PREFERENCES; INJECTIONS, INTRAPERITONEAL; KETAMINE; MALE; METHYLPHENIDATE; RATS; RATS, SPRAGUE-DAWLEY; REINFORCEMENT (PSYCHOLOGY); REINFORCEMENT SCHEDULE; SELF ADMINISTRATION; SUCROSE; SWEETENING AGENTS; TIME FACTORS;

EID: 84858335405     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.226     Document Type: Article

References (49)

1. Baird TJ, Deng SX, Landry DW, Winger G, Woods JH (2000). Natural and artificial enzymes against cocaine. I. Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats. J Pharmacol Exp Ther 295: 1127-1134.
2. Barrett AC, Miller JR, Dohrmann JM, Caine SB (2004). Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats. Neuropharmacology 47(Suppl 1): 256-273.
3. Barrett AC, Negus SS, Mello NK, Caine SB (2005). Effect of GABA agonists and GABA-A receptor modulators on cocaine- and food-maintained responding and cocaine discrimination in rats. J Pharmacol Exp Ther 315: 858-871.
4. Bresler MM, Rosser SJ, Basran A, Bruce NC (2000). Gene cloning and nucleotide sequencing and properties of a cocaine esterase from Rhodococcus sp. strain MB1. Appl Environ Microbiol 66: 904-908.
5. Brim RL, Nance MR, Youngstrom DW, Narasimhan D, Zhan CG, Tesmer JJ et al (2010). A thermally stable form of bacterial cocaine esterase: A potential therapeutic agent for treatment of cocaine abuse. Mol Pharmacol 77: 593-600.
6. Brim RL, Noon KR, Nichols J, Narasimhan D, Woods JH, Sunahara RK (2011). Evaluation of the hydrolytic activity of a long-acting mutant bacterial cocaine in the presence of commonly coadministered drugs. Drug Alcohol Depend; e-pub ahead of print 18 July 2011; doi:10.1016/j.drugalcdep.2011.06.018.
7. Brimijoin S, Gao Y, Anker JJ, Gliddon LA, Lafleur D, Shah R et al (2008). A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 33: 2715-2725.
8. Caliceti P, Veronese FM (2003). Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 55: 1261-1277.
9. Carmona GN, Schindler CW, Greig NH, Holloway HW, Jufer RA, Cone EJ et al (2005). Intravenous butyrylcholinesterase administration and plasma and brain levels of cocaine and metabolites in rats. Eur J Pharmacol 517: 186-190.
10. Carrera MR, Ashley JA, Zhou B, Wirsching P, Koob GF, Janda KD (2000). Cocaine vaccines: Antibody protection against relapse in a rat model. Proc Natl Acad Sci USA 97: 6202-6206.
11. Carroll ME, Gao Y, Brimijoin S, Anker JJ (2011). Effects of cocaine hydrolase on cocaine self-administration under a PR schedule and during extended access (escalation) in rats. Psychopharmacology (Berl) 213: 817-829.
12. Collins GT, Brim RL, Narasimhan D, Ko MC, Sunahara RK, Zhan CG et al (2009). Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats. J Pharmacol Exp Ther 331: 445-455.
13. Collins GT, Carey KA, Narasimhan D, Nichols J, Berlin AA, Lukacs NW et al (2011a). Amelioration of the cardiovascular effects of cocaine in rhesus monkeys by a long-acting mutant form of cocaine esterase. Neuropsychopharmacology 36: 1047-1059.
14. Collins GT, Zaks ME, Cunningham AR, St Clair C, Nichols J, Narasimhan D et al (2011b). Effects of a long-acting mutant bacterial cocaine esterase on acute cocaine toxicity in rats. Drug Alcohol Depend; e-pub ahead of print 9 April 2011; doi:10.1016/j.drugalcdep.2011.1003.1015.
15. Cooper ZD, Narasimhan D, Sunahara RK, Mierzejewski P, Jutkiewicz EM, Larsen NA et al (2006). Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol Pharmacol 70: 1885-1891.
16. Dackis C, O'Brien C (2003). Glutamatergic agents for cocaine dependence. Ann NY Acad Sci 1003: 328-345.
17. Fox BS, Kantak KM, Edwards MA, Black KM, Bollinger BK, Botka AJ et al (1996). Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 2: 1129-1132.
18. Gao D, Narasimhan DL, Macdonald J, Brim R, Ko MC, Landry DW et al (2009). Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol Pharmacol 75: 318-323.
19. Grabowski J, Shearer J, Merrill J, Negus SS (2004). Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 29: 1439-1464.
20. Haney M, Gunderson EW, Jiang H, Collins ED, Foltin RW (2010). Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry 67: 59-65.
21. Hiranita T, Soto PL, Newman AH, Katz JL (2009). Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: Comparisons with monoamine uptake inhibitors. J Pharmacol Exp Ther 329: 677-686.
22. Jutkiewicz EM, Baladi MG, Cooper ZD, Narasimhan D, Sunahara RK, Woods JH (2009). A bacterial cocaine esterase protects against cocaine-induced epileptogenic activity and lethality. Ann Emerg Med 54: 409-420.
23. Kantak KM, Collins SL, Lipman EG, Bond J, Giovanoni K, Fox BS (2000). Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl) 148: 251-262.
24. Ko MC, Bowen LD, Narasimhan D, Berlin AA, Lukacs NW, Sunahara RK et al (2007). Cocaine esterase: Interactions with cocaine and immune responses in mice. J Pharmacol Exp Ther 320: 926-933.
25. Ko MC, Narasimhan D, Berlin AA, Lukacs NW, Sunahara RK, Woods JH (2009). Effects of cocaine esterase following its repeated administration with cocaine in mice. Drug Alcohol Depend 101: 202-209.
26. Landry DW, Yang GX (1997). Anti-cocaine catalytic antibodiesFa novel approach to the problem of addiction. J Addict Dis 16: 1-17.
27. Landry DW, Zhao K, Yang GX, Glickman M, Georgiadis TM (1993). Antibody-catalyzed degradation of cocaine. Science 259: 1899-1901.
28. Larsen NA, Turner JM, Stevens J, Rosser SJ, Basran A, Lerner RA et al (2002). Crystal structure of a bacterial cocaine esterase. Nat Struct Biol 9: 17-21.
29. Lynch TJ, Mattes CE, Singh A, Bradley RM, Brady RO, Dretchen KL (1997). Cocaine detoxification by human plasma butyrylcholinesterase. Toxicol Appl Pharmacol 145: 363-371.
30. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR (2005). Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 58: 158-164.
31. Mello NK (1990). Preclinical evaluation of the effects of buprenorphine, naltrexone and desipramine on cocaine selfadministration. NIDA Res Monogr 105: 189-195.
32. Mello NK, Bowen CA, Mendelson JH (2002). Comparison of plasma cocaine levels during a 'binge' pattern of cocaine administration in male and female rhesus monkeys. Psychopharmacology (Berl) 164: 19-26.
33. Mendelson JH, Mello NK, Sholar MB, Siegel AJ, Kaufman MJ, Levin JM et al (1999). Cocaine pharmacokinetics in men and in women during the follicular and luteal phases of the menstrual cycle. Neuropsychopharmacology 21: 294-303.
34. Mets B, Winger G, Cabrera C, Seo S, Jamdar S, Yang G et al (1998). A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats. Proc Natl Acad Sci USA 95: 10176-10181.
35. Narasimhan D, Collins GT, Nance MR, Nichols J, Edwald E, Chan J et al (2011). Subunit stabilization and PEGylation of cocaine esterase improves in vivo residence time. Mol Pharmacol; e-pub ahead of print 2 September 2011.
36. Narasimhan D, Nance MR, Gao D, Ko MC, Macdonald J, Tamburi P et al (2010). Structural analysis of thermostabilizing mutations of cocaine esterase. Protein Eng Des Sel 23: 537-547.
37. Pan Y, Gao D, Yang W, Cho H, Yang G, Tai HH et al (2005). Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc Natl Acad Sci USA 102: 16656-16661.
38. Platt DM, Rowlett JK, Spealman RD (2002). Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology (Berl) 163: 265-282.
39. Roberts DC, Brebner K (2000). GABA modulation of cocaine selfadministration. Ann NY Acad Sci 909: 145-158.
40. Tanda G, Newman AH, Katz JL (2009). Discovery of drugs to treat cocaine dependence: Behavioral and neurochemical effects of atypical dopamine transport inhibitors. Adv Pharmacol 57: 253-289.
41. Turner JM, Larsen NA, Basran A, Barbas III CF, Bruce NC, Wilson IA et al (2002). Biochemical characterization and structural analysis of a highly proficient cocaine esterase. Biochemistry 41: 12297-12307.
42. Ukai M, Holtzman SG (1988). Restricted feeding does not modify discriminative stimulus effects of morphine in the rat. Pharmacol Biochem Behav 29: 201-203.
43. UNODC (2010). World Drug Report 2010.
44. Vocci FJ, Acri J, Elkashef A (2005). Medication development for addictive disorders: The state of the science. Am J Psychiatry 162: 1432-1440.
45. Wood SK, Narasimhan D, Cooper Z, Sunahara RK, Woods JH (2010). Prevention and reversal by cocaine esterase of cocaineinduced cardiovascular effects in rats. Drug Alcohol Depend 106: 219-229.
46. Woolfolk DR, Holtzman SG (1997). mu-, delta- and kappa-opioid receptor agonists do not alter the discriminative stimulus effects of cocaine or d-amphetamine in rats. Drug Alcohol Depend 48: 209-220.
47. Xue L, Ko MC, Tong M, Yang W, Hou S, Fang L et al (2010). Design, preparation and characterization of high-activity mutants of human butyrylcholinesterase specific for detoxification of cocaine. Mol Pharmacol 79: 290-297.
48. Zhan CG, Zheng F, Landry DW (2003). Fundamental reaction mechanism for cocaine hydrolysis in human butyrylcholinesterase. J Am Chem Soc 125: 2462-2474.
49. Zheng F, Yang W, Ko MC, Liu J, Cho H, Gao D et al (2008). Most efficient cocaine hydrolase designed by virtual screening of transition states. J Am Chem Soc 130: 12148-12155.